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with an estimated 2-year survival of 13% 2 and a median overall survival (OS) period of 12 months. 3 There have been no previous reports regarding the efficacy of allogeneic hematopoietic SCT (Allo-HSCT) in adult AML with t(6;11)(q27;q23) in the first CR. In this study, we performed a retrospective analysis of data from nine adult AML patients with t(6;11)(q27;q23) aged o60 years in the first CR to clarify the effects of Allo-HSCT in adult AML with this chromosomal abnormality in the first CR.
Data from nine adult (X17 years old) AML patients with t(6;11)(q27;q23) aged o60 years, diagnosed between 1990 and 2006 at six institutions in Japan, were included in the retrospective analysis. Chromosomal analysis was performed after culturing BM cells for 24-48 h. Twenty metaphase cells were analyzed after trypsin-Giemsa banding.
The main endpoints in the analysis of treatment outcome were EFS, disease-free survival (DFS) and overall OS. The duration of EFS was measured from the start of therapy to the date of the first treatment failure of any event (relapse, second malignancy or death) or to the last date of followup. OS was measured from the start of therapy to the date of death or to the last follow-up. Patients who did not achieve CR were regarded as showing treatment failure at time zero. DFS was the same as EFS for patients who achieved the CR. The distributions of EFS, DFS and OS were estimated by the Kaplan-Meier method. The exact log-rank test was used to compare clinical outcome distributions.
The median duration of the follow-up for all patients was 17 months (range, 4-45 months). Allo-HSCT was performed in six of nine AML patients who achieved the first CR (matched-related donor, four; matched-unrelated donor, two). In all six cases, Allo-HSCT was performed with a myeloablative regimen. Three patients in the first CR who did not undergo Allo-HSCT received at least two episodes of high-dose Ara-C (cytarabine), as consolidation therapy.
The prognosis was compared between patients aged o60 years treated with (n ¼ 6) and without Allo-HSCT (n ¼ 3) after achieving the first CR in induction therapy to determine the efficiency of Allo-HSCT during the first CR. The clinical characteristics of nine AML patients aged o60 years who attained the first CR in induction therapy are shown in Table 1 . Figure 1 shows DFS and OS curves of nine adult patients aged o60 years with AML with 11q23 abnormalities in the first CR with Allo-HSCT vs those without HSCT. The 1-year DFS rate and 2-year OS rate in AML patients with 11q23 abnormalities treated with Allo-HSCT were 60.0 and 66.6%, respectively. These results were better than those in patients without Allo-HSCT (0.0 and 0.0%, respectively), and the difference was statistically significant for OS (P ¼ 0.045).
To our knowledge, this is the first report regarding the efficacy of Allo-HSCT in patients with adult AML with t(6;11)(q27;q23). We have previously reported regarding the efficacy of Allo-HSCT in patients with adult AML with 11q23 abnormalities although the efficacy was not statistically significant. 4 It should be noted that the patients aged o60 years old with AML with t(6;11)(q27;q23) in the first CR treated with Allo-HSCT showed significantly better OS than those treated without Allo-HSCT. The differences in DFS were Table 1 Clinical characteristics of 9 AML patients with t(6;11)(q27;q23) aged o60 years who attained the first CR Figure 1 (a) OS curves of adult AML patients with t(6;11)(q27;q23) aged o60 years in the first CR with Allo-HSCT vs those without HSCT.
(b) DFS curves of adult AML patients with t(6;11)(q27;q23) aged o60 years in the first CR with Allo-HSCT vs those without HSCT. Allo-HSCT, allogeneic hematopoietic SCT, DFS, disease-free survival; OS, overall survival.
